Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of April 2022, with a specific transaction date of April 7, 2022. The report serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details a specific securities transaction:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Type: Acquisition of notional ADSs within an Executive Supplemental Savings Plan account.
- Price: $46.2300 per ADS.
- Volume: 1,114.171 ADSs.
- Exchange: New York Stock Exchange (XNYS).
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely documents a routine executive compensation-related transaction.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is a regulatory disclosure of a specific insider transaction.
Key Facts for Investor Verification
- Executive Involved: Dr. H Barron, Chief Scientific Officer and President, R&D.
- Transaction Nature: Acquisition of notional shares via a savings plan, not a direct open-market purchase.
- Transaction Date: April 7, 2022.
- Reporting Date: April 12, 2022.